Trial Profile
A Randomized, Double Blind, Placebo Controlled, Parallel Group, Phase 3 Study of MAP0004 in Adult Migraineurs for a Single Migraine Followed by Open Label Extension.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 May 2015
Price :
$35
*
At a glance
- Drugs Dihydroergotamine mesilate (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Acronyms FREEDOM-301
- Sponsors MAP Pharmaceuticals
- 02 Aug 2011 Results from the primary part of the trial and the long-term safety extension were used as the basis of a NDA, which has been submitted to the US FDA.
- 07 Apr 2011 Full results of the study were published in the journal Headache, according to a MAP Pharmaceuticals media release.
- 01 Apr 2011 Results published in the Headache.